![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Deciphera’s Qinlock for Gastrointestinal Stromal Tumor
FDA Approves Deciphera’s Qinlock for Gastrointestinal Stromal Tumor
May 19, 2020
The FDA approved Decipharma Pharmaceuticals’ Qinlock (ripretinib) as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).
The approval was based on the results of a study of 129 patients with advanced GIST who received prior treatment with imatinib, sunitinib, and regorafenib.
Progression-free survival in participants taking Qinlock was 6.3 months, compared to one month for those taking placebo.
Qinlock was granted priority review, fast track, and breakthrough therapy designations.
Upcoming Events
-
21Oct